W
WAVEMAN · COMPANY
PTGX · Protagonist Therapeutics, Inc
> Ask across nine datasets ⌘K
LIVE
TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475
← ALL COMPANIES

PTGX

Protagonist Therapeutics, Inc
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001377121
FORM 144 · 2☆ WATCH
INSIDER NET · 180D
-$51.1M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
205
13F, latest reported quarter
REVENUE GROWTH
-89.4%
XBRL, annual
NET MARGIN
-282.8%
CONVERSIONS · 180D
16
codes C/M, not in net · $7.4M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$51.1M over 180 days
-$16.9M over 90 days
below 94% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
205 funds added or opened last quarter
more than 88% of Pharma & Biotech
REVENUE
-89.4% year over year
below 91% of Pharma & Biotech
MARGIN
-282.8% net margin
below 76% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$51.1M across 6 people in 180 days.
205 funds added or opened positions in the latest 13F quarter, of 351 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +147.6%
+147.6%12M
-5%+53%+112%+170%2025-092025-102025-122026-032026-052026-072026-09 2026-08-10 · PATEL DINESH V PH D sold $9.8M2026-05-12 · PATEL DINESH V PH D sold $7.5M2026-05-12 · PATEL DINESH V PH D sold $7.5M2026-03-25 · PATEL DINESH V PH D sold $5.5M2026-08-11 · PATEL DINESH V PH D sold $5.1M2026-05-07 · Giraudo Bryan sold $3.6M2026-01-20 · PATEL DINESH V PH D sold $2.8M2026-03-26 · Ali Asif sold $2.6M2026-03-26 · SELICK HAROLD E sold $2.5M2026-01-27 · Ali Asif sold $2.3M2026-02-06 · Waddill William D. sold $1.7M2026-01-23 · PATEL DINESH V PH D sold $1.6M2026-03-26 · MOLINA ARTURO MD sold $1.6M2026-01-27 · Ali Asif sold $1.5M2026-02-17 · Williams Lewis T sold $1.5M2026-05-07 · Giraudo Bryan sold $1.2M2026-01-26 · PATEL DINESH V PH D sold $1.2M2026-01-23 · MOLINA ARTURO MD sold $1.1M2026-06-23 · Waddill William D. sold $1.1M2026-06-10 · Waddill William D. sold $969.1K2026-01-26 · PATEL DINESH V PH D sold $897.5K2026-05-29 · Waddill William D. sold $896.8K2026-01-20 · MOLINA ARTURO MD sold $784.7K2026-01-20 · Ali Asif sold $708.3K2025-10-10 · Waddill William D. sold $702.5K2026-05-08 · Giraudo Bryan sold $600.0K2026-05-08 · Giraudo Bryan sold $513.0K2026-01-26 · MOLINA ARTURO MD sold $411.4K2026-01-27 · MOLINA ARTURO MD sold $410.0K2026-01-27 · PATEL DINESH V PH D sold $338.4K2025-10-10 · Waddill William D. sold $277.0K2025-09-22 · Waddill William D. sold $257.0K2025-11-17 · MOLINA ARTURO MD sold $229.9K2026-04-20 · Ali Asif sold $184.6K2026-03-24 · PATEL DINESH V PH D sold $6.0K2026-08-10 · Dinesh Patel filed to sell $33.6M2026-06-23 · WILLIAM WADDILL filed to sell $1.0M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $51.1M sold by insiders over 180 days, 205 funds added last quarter, $34.6M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Protagonist Therapeutics, Inc insiders sold a net $51.1M of stock across 74 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER
FILED
SHARES
VALUE
PATEL DINESH V PH D
President and CEO
SELL
2026-08-11
34,239.0
$5.1M
PATEL DINESH V PH D
President and CEO
SELL
2026-08-10
65,761.0
$9.8M
Waddill William D.
Director
SELL
2026-06-23
9,000.0
$1.1M
Waddill William D.
Director
SELL
2026-06-10
9,000.0
$969.1K
Waddill William D.
Director
SELL
2026-05-29
9,000.0
$896.8K
74 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 69 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
10,307,837.0 sh
$1.3B
FARALLON CAPITAL MANAGEMENT, L.L.C.
6,348,906.0 sh
$778.2M
RTW INVESTMENTS, LP
5,061,175.0 sh
$620.4M
VANGUARD PORTFOLIO MANAGEMENT LLC
3,629,298.0 sh
$444.9M
WELLINGTON MANAGEMENT GROUP LLP
3,416,781.0 sh
$418.8M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Dinesh Patel
FILED 2026-08-10
$33.6M
WILLIAM WADDILL
FILED 2026-06-23
$1.0M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Invesco S&P SmallCap Health Care ETF
$4.5M POSITION · AS OF 2026-02-28
3.2%
Invesco Biotechnology & Genome ETF
$8.0M POSITION · AS OF 2026-04-30
3.2%
AlphaCentric Life Sciences and Healthcare Fund
$952.8K POSITION · AS OF 2026-03-31
2.4%
Pacer US Small Cap Cash Cows Growth Leaders ETF
$486.5K POSITION · AS OF 2026-04-30
2.1%
iShares Health Innovation Active ETF
$201.0K POSITION · AS OF 2026-04-30
2.0%
SBH SMALL CAP GROWTH FUND
$5.6M POSITION · AS OF 2026-03-31
1.9%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 8 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
0 ACTIVE
5
Phase 2
0 ACTIVE
2
Phase 3
2 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Dr. Patel
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2023
$7.1M
$15.3M
$1.8M
+14%
—
2022
$6.0M
-$5.2M
$2.5M
-46%
—
2021
$5.5M
$12.1M
$2.2M
+70%
—
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$46.0M$434.4M$60.0M$26.6M
OPERATING INCOME$-158.1M$252.8M$-93.7M$-131.4M
NET INCOME$-130.1M$275.2M$-79.0M$-127.4M
EPS (DILUTED)-2.054.23-1.39-2.60
OPERATING CASH FLOW$57.7M$184.2M$-70.2M$-108.1M
CASH$128.4M$97.2M$186.7M$125.7M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-06 ALL SYSTEMS LIVE FOR MACHINES →